Advertisement
Australia markets closed

  • ALL ORDS

    8,022.70
    +28.50 (+0.36%)
     

  • ASX 200

    7,749.00
    +27.40 (+0.35%)
     

  • AUD/USD

    0.6621
    -0.0001 (-0.01%)
     

  • OIL

    79.82
    +0.56 (+0.71%)
     

  • GOLD

    2,371.60
    +31.30 (+1.34%)
     

  • Bitcoin AUD

    95,236.32
    +2,822.15 (+3.05%)
     

  • CMC Crypto 200

    1,303.49
    -54.52 (-4.02%)
     

  • AUD/EUR

    0.6135
    -0.0003 (-0.05%)
     

  • AUD/NZD

    1.0976
    +0.0007 (+0.07%)
     

  • NZX 50

    11,755.17
    +8.59 (+0.07%)
     

  • NASDAQ

    18,229.60
    +116.13 (+0.64%)
     

  • FTSE

    8,440.66
    +59.31 (+0.71%)
     

  • Dow Jones

    39,548.27
    +160.51 (+0.41%)
     

  • DAX

    18,781.66
    +95.06 (+0.51%)
     

  • Hang Seng

    18,963.68
    +425.87 (+2.30%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

Entera Bio Ltd. (ENTX) Stock Slides as Market Rises: Facts to Know Before You Trade

Zacks Equity Research
·2-min read

Entera Bio Ltd. (ENTX) closed at $1.98 in the latest trading session, marking a -1% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 1.02%. Meanwhile, the Dow gained 0.4%, and the Nasdaq, a tech-heavy index, added 2.03%.

Shares of the company witnessed a gain of 19.76% over the previous month, beating the performance of the Medical sector with its loss of 5.2% and the S&P 500's loss of 3.15%.

The investment community will be paying close attention to the earnings performance of Entera Bio Ltd. in its upcoming release. The company is expected to report EPS of -$0.06, up 25% from the prior-year quarter.

Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Entera Bio Ltd. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.

ADVERTISEMENT

Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 66.67% upward. At present, Entera Bio Ltd. boasts a Zacks Rank of #1 (Strong Buy).

The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 75, finds itself in the top 30% echelons of all 250+ industries.

The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Entera Bio Ltd. (ENTX) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research